Enterprise Therapeutics Strengthens Leadership Team, Appoints Amit D. Munshi as Non-Executive Chairman
Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a
Epidarex Capital Continues Expansion of its Team
Epidarex Capital, a leading early stage life science firm, is delighted to announce the addition of two veteran life science professionals to its transatlantic team.
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM,
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains
AdoRx Therapeutics Announces Collaboration with Johnson & Johnson Innovation to Develop Novel Lung Cancer Therapeutics
Edinburgh, Scotland, 28th February, 2019 – AdoRx Therapeutics, a UK based drug discovery company, today announced that it has entered into a strategic collaboration with
Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
New designation now includes all PNH patients CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development
Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases
Sirakoss Receives CE Mark For Osteo3 Synthetic Bone Graft Substitute
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the